Clinical Trial

A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a multicenter, open label, randomized Phase 3 clinical study to evaluate tobevibart + elebsiran in participants with Chronic HDV Infection not virologically suppressed with bulevirtide
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-07-14
Trial Details
NCT Number NCT07128550
Lead Sponsor Vir Biotechnology, Inc.
Conditions Viral Hepatitis
Enrollment 150 participants
Start Date 2025-07-30
Primary Completion 2026-12 (estimated)
Study Completion 2031-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-13